Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)

PHASE1RecruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

May 31, 2028

Conditions
PD - Parkinson's Disease
Interventions
COMBINATION_PRODUCT

Human induced pluripotent stem cell-derived dopaminergic progenitors (CT1-DAP001)

"Investigational PET agents will be synthesized at UCSD and administered to subjects according to the local institutional guidelines. IND applications for these agents are linked with the IND application for the study product, CT1-DAP001. The IND applications for the PET radiopharmaceuticals contains the manufacturing method, specifications, quality testing, clinical usage, and safety and efficacy information for individual PET agents.~Investigational Cell Injector Suniviion needle: The investigational instrument will be used to administer dopaminergic progenitors into the putamen. After aspirating cells, the instrument will be attached to a Leksell stereotactic frame to administer the cells into the brain."

Trial Locations (1)

92037

RECRUITING

University of California, San Diego, La Jolla

All Listed Sponsors
collaborator

Sumitomo Pharma America, Inc.

INDUSTRY

collaborator

Kyoto University

OTHER

collaborator

Sumitomo Pharma Co., Ltd.

INDUSTRY

collaborator

CiRA Foundation

UNKNOWN

lead

University of California, San Diego

OTHER